Venture Studio
What is Venture Studio?
A purpose-built drug discovery venture creation engine which offers a collaborative model to generate scientific concepts and translate them into high-confidence drug candidates, powered by RxAgentAi- an AI-enabled discovery engine that advances ideas through a disciplined, milestone-led path into de-risked, IND-ready programs and partner- or spin-out-ready biotech ventures.
Why Venture Studio?
Drug discovery doesn’t fail due to lack of data-it fails due to fragmentation, bias, and slow execution. Our Venture Studio integrates AI intelligence, scientific rigor, and venture discipline into a single, repeatable system that consistently converts ideas into value.
How it works?
Idea Intake & Scientific Framing
High-potential ideas are evaluated against unmet medical needs and refined into clear, testable discovery hypotheses.
AI-Enabled Discovery
RxAgentAi accelerates target identification, validation, and lead generation using integrated biological, chemical, and translational intelligence.
Integrated Scientific Execution
VedTechBio’s in-house experts execute programs across discovery and translation to generate decision-grade data.
Parallel Program Incubation
Multiple programs are incubated concurrently using shared infrastructure to maximize speed and capital efficiency.
What it Delivers?
IND-Enabling Candidates
Target Product Profile (TPP) - aligned development candidates ready for toxicology and IND-enabling studies.
Accelerated Timelines
Pre-IND readiness achieved in 12–24 months versus 3–4 years traditionally.
Capital Efficiency
IND-ready assets delivered at $1.5–2.0M per program versus $15–20M.
De-Risked Preclinical Packages
Integrated biology, chemistry, and translational datasets reducing late-stage risk.
Partner-Ready Value Inflection
Early discovery alone typically takes 3-4 years before pre-clinical studies.
Repeatable Venture Output
A scalable engine for continuous venture creation.